CLAIMS

1. Use of a composition comprising either

a) alpha-linolenic acid (ALA, C18:3 n-3) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; or

b) docosahexaenoic acid (DHA, C22:6 n-3) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; or

c) DHA in admixture with eicosapentaenoic acid (EPA, C20:5 n-3) , in a ratio of 1:0.5 to 1:1.7, respectively, and/or the pharmaceutically acceptable derivatives and/or precursors thereof;

either a) or b) or c) being in a concentration not lower than 70% by weight of the total fatty acids weight in the composition, for the preparation of a drug for the prevention and/or treatment of the psychiatric disturbances of the central nervous system (CNS) selected from the group consisting of schizophrenia, manic-depressive syndrome, major depression, and Alzheimer's disease;

with the provisos that:

when the composition comprises b), arachidonic acid is not added thereto; and

when the composition comprises c), it does not comprise 10 to 40% by weight of reducing/antioxidant vitamins or provitamins.

~~CLAIMS~~

~~1. Use of a composition comprising either~~

a) alpha-linolenic acid (ALA, C18:3 n-3) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; or

b) docosahexaenoic acid (DHA, C22:6 n-3) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; or

c) DHA in admixture with eicosapentaenoic acid (EPA, C20:5 n-3) , in a ratio of 1:0.5 to 1:1.7, respectively, and/or the pharmaceutically acceptable derivatives and/or precursors thereof;

either a) or b) or c) being in a concentration not lower than 70% by weight of the total fatty acids weight in the composition, for the preparation of a drug for the prevention and/or ~~treatment of the disturbances of the central nervous system (CNS).~~

~~2. Use according to claim 1, wherein the disturbances of CNS are neurological and/or~~ psychiatric disturbances.

3. Use according to claim 1 or 2, wherein the disturbances of CNS are epilepsy, schizophrenia, manic-depressive syndrome, ~~major~~ depression, and Alzheimer's disease.

4. Use according to the ~~previous~~ claim, wherein epilepsy shows partial and/or generalized seizures.

~~5. Use according to claim 3 or 4, wherein epilepsy shows simple and/or complex seizures.~~

~~6~~ 2. Use according to claim ~~3~~ 1, wherein schizophrenia shows negative and/or positive symptoms.

~~7~~ 3. Use according to claim ~~3 or 6~~ 1 or 2, wherein schizophrenia is paranoid, catatonic, disorganised or undifferentiated schizophrenia.

~~8~~ 4. Use according to ~~claim 3~~ any of the previous claims, wherein the manic-depressive syndrome and major depression include disorders of mood, behaviour and autonomic functions correlated to activity, sleep and appetite.

~~9~~ 5. Use according to claim ~~3~~ 1, wherein the Alzheimer's disease includes the various related forms of dementia.

~~10~~ 6. Use according to any of the previous claims, wherein the ratio of DHA to EPA in c) is of 1:0.9 to 1:1.5.

~~11~~ 7. Use according to any of the previous claims, wherein the concentration of either a) or b) or c) is of 75% to 95% by weight of the total fatty acids weight in the composition.

~~12~~ 8. Use according to any of the previous claims, wherein the concentration of either a) or b) or c) is of 80% to 90% by weight of the total fatty acids weight in the composition.

~~13~~ 9. Use according to any of the previous claims, wherein the concentration of either a) or b)

or c) is of 85% by weight of the total fatty acids weight in the composition.

10. ~~14~~. Use according to any of the previous claims, wherein the composition comprises at least another n-3 and/or n-6 polyunsaturated and/or monounsaturated and/or saturated fatty acid.

11. ~~15~~. Use according to the previous claim, wherein the composition comprises at least two other n-3 and/or n-6 polyunsaturated and/or monounsaturated and/or saturated fatty acids, in any ratio among themselves.

12. ~~16~~. Use according to claim ~~14 or 15~~ 10 or 11 wherein the other n-3 and/or n-6 polyunsaturated and/or monounsaturated and/or saturated fatty acids are in a concentration of lower or equal to 30%.

13. ~~17~~. Use according to any of the previous claims, wherein the derivatives of ALA, DHA and EPA are selected from the group consisting of their C_1-C_3 alkyl esters, glyceride mono-, di-, tri-esters, salts with pharmaceutically acceptable bases, whereas the precursors of ALA, DHA and EPA are the compounds able to lead to them through *in vivo* transformations.

14. ~~18~~. Use according to any of the previous claims, wherein the drug comprises essentially DHA ethyl ester and EPA ethyl ester.

15. ~~19~~. Use according to any of the previous claims, wherein the drug is administered by oral route.

16. ~~20~~. Use according to any of the previous claims, wherein the drug is in the form of soft gelatine capsules.

17. ~~21~~. Use according to any of the previous claims, wherein the drug is administered at the dose of 0.1-5 g/day.

18. ~~22~~. Use according to any of the previous claims, wherein the drug is administered at the dose of 0.3-3 g/day.

19. ~~23~~. Use according to any of the previous claims, wherein the drug is administered at the dose of 1-2 g/day.

20. ~~24~~. Use according to any of the previous claims, wherein the drug is administered separately, as a coadjuvant or an auxiliary drug, from at least another drug effective for the prevention and/or treatment of the disturbances of CNS.

21. ~~25~~. Use according to any of the previous claims, wherein the drug comprises at least another drug effective for the prevention and/or treatment of the disturbances of CNS.

~~26. A method for prevention and/or treatment of CNS disturbances in a mammal in need~~ thereof comprising administering to the mammal a therapeutically ~~effective~~ dose of a drug as defined in any of the previous claims.

27. A method ~~according to~~ the previous claim, wherein the therapeutically effective dose ~~ranges from about 2 to 60 mg/kg of the mammal body weight per day.~~

~~28. A method according to claim 26 or 27, wherein the CNS disturbances are epilepsy, schizophrenia, manic- depressive syndrome, major depression and Alzheimer's disease.~~